# A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms

> **NCT00817986** · PHASE2 · COMPLETED · sponsor: **XenoPort, Inc.** · enrollment: 161 (actual)

## Conditions studied

- Back Pain

## Interventions

- **DRUG:** Arbaclofen placarbil, 20 mg
- **DRUG:** Placebo
- **DRUG:** Arbaclofen placarbil, 30 mg
- **DRUG:** Arbaclofen placarbil, 40 mg

## Key facts

- **NCT ID:** NCT00817986
- **Lead sponsor:** XenoPort, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00817986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00817986, "A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00817986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*